Top-News
Biotechnologie USA

MannKind News

Aktie
WKN:  A2DMZL ISIN:  US56400P7069 US-Symbol:  MNKD
4,071 €
-0,011 €
-0,27%
10:36:59 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
264,31 Mio.
Marktkapitalisierung *
1,08 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 09.08.2023

MannKind News

02.03.23 - Der Aktionär
Eli Lilly: Preisdeckel für Insulin erhöht Druck auf andere Pharmakonzerne
24.02.23 - PR Newswire
Thinking about buying stock in Timber Pharmaceuticals, Warner Bros, Alibaba, MannKind, or ON Semiconductor?
Thinking about buying stock in Timber Pharmaceuticals, Warner Bros, Alibaba, MannKind, or ON Semiconductor? PR Newswire
04.10.21 - PR Newswire
MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population
MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population • Multi-​center study to assess the efficacy and safety of Afrezza in patients aged 4-17 ...
07.09.21 - PR Newswire
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021 In subjects with PAH, transition from Tyvaso® to ...
04.08.21 - PR Newswire
NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions
NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions - ZYESAMI™ (aviptadil) was awarded Fast Track ...
04.08.21 - PR Newswire
MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform
MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform NRx was granted Fast Track ...
28.06.21 - PR Newswire
Thinking about buying stock in Anavex Life Sciences, Arbutus Biopharma, MannKind, Perion Network, or Precision BioSciences?
Thinking about buying stock in Anavex Life Sciences, Arbutus Biopharma, MannKind, Perion Network, or Precision BioSciences? PR Newswire
28.06.21 - PR Newswire
Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza® And Continuous Glucose Monitoring Devices Beginning July 18
Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza® And Continuous Glucose Monitoring Devices Beginning July 18 - Restriction of ...
25.06.21 - PR Newswire
MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29
MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29 - Poster 923-P: Phase 2 clinical study results revealed similar ...
16.06.21 - PR Newswire
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA - Tyvaso DPI includes the ...
16.06.21 - PR Newswire
Thinking about buying stock in Catabasis Pharmaceuticals, Arrival, MannKind, Trevena, or Altimmune?
Thinking about buying stock in Catabasis Pharmaceuticals, Arrival, MannKind, Trevena, or Altimmune? PR Newswire
16.06.21 - PR Newswire
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review FDA action expected in October 2021 PR Newswire
03.06.21 - PR Newswire
MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5
MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5 Post ...
20.05.21 - PR Newswire
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-karts With Local Youth On Tuesday, May 25th
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-karts With Local Youth On Tuesday, May 25th Indiana native living with Type 1 diabetes is sharing ...
13.05.21 - PR Newswire
MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly
MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly Daly to drive bold "Tired of Pricks?" design for Ed Carpenter Racing at GMR Grand Prix on May 15 ...
10.11.20 - PR Newswire
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MannKind Corporation for Potential Breaches of Fiduciary Duty By Its Board of Directors
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MannKind Corporation for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire
16.10.18 - PR Newswire
United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement
United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement PR Newswire
04.09.18 - PR Newswire
United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products
United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products Exclusive license agreement for Treprostinil Technosphere®; $95 million in ...
25.07.18 - The Motley Fool
Sollten die Biotech-Investoren eine Verwässerung fürchten?
Verwässerung ist ein zentrales Anliegen für Biotech-​Investoren. Grundsätzlich geht es darum, dass Biotechs im Entwicklungsstadium oder im frühen kommerziellen Stadium stark ...
19.10.17 - The Motley Fool
7 Grundregeln für das Investieren in Biotech-Aktien
Erfolgreich investieren bedeutet, das Risiko zu minimieren und gleichzeitig das Renditepotenzial zu maximieren. Ob man in Aktien, Anleihen, Kryptowährungen oder in etwas ...

Newssuche

Videos

newspaper
13:20 Uhr +42,11%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »